162 related articles for article (PubMed ID: 37382209)
21. Robotic interval debulking surgery for advanced epithelial ovarian cancer: current challenge or future direction? A systematic review.
Psomiadou V; Prodromidou A; Fotiou A; Lekka S; Iavazzo C
J Robot Surg; 2021 Apr; 15(2):155-163. PubMed ID: 33037532
[TBL] [Abstract][Full Text] [Related]
22. Bowel resection or repair at the time of cytoreductive surgery for ovarian malignancy is associated with increased complication rate: An ACS-NSQIP study.
Bernard L; Boucher J; Helpman L
Gynecol Oncol; 2020 Sep; 158(3):597-602. PubMed ID: 32641239
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
[TBL] [Abstract][Full Text] [Related]
24. Mechanical and oral antibiotic bowel preparation in ovarian cancer debulking: Are we lowering or just trading surgical complications?
Wang CC; Al-Rubaye R; Tran V; Montemorano L; Al-Niaimi A
Gynecol Oncol; 2022 Jul; 166(1):76-84. PubMed ID: 35589434
[TBL] [Abstract][Full Text] [Related]
25. Minilaparotomy, Cyfra21-1, and Other Predicting Factors for Suboptimal Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer: A Pilot Study.
Nantasupha C; Pojchamarnwiputh S; Charoenkwan K
Asian Pac J Cancer Prev; 2022 Dec; 23(12):4119-4124. PubMed ID: 36579993
[TBL] [Abstract][Full Text] [Related]
26. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
27. Low anterior resection syndrome (LARS) in patients with epithelial ovarian cancer after primary debulking surgery.
Kranawetter M; Ataseven B; Grimm C; Schneider S; Riss S; Alesina P; Prader S; Walz MK; Harpain F; Stift A; Heitz F; Reinthaller A; Polterauer S; Harter P; du Bois A
Gynecol Oncol; 2019 Sep; 154(3):577-582. PubMed ID: 31235241
[TBL] [Abstract][Full Text] [Related]
28. Unanticipated 30-day readmission following rectosigmoid resection at the time of cytoreductive surgery in patients with advanced stage ovarian cancer.
Sanders BE; Saharti S; Laus K; Bristow RE; Eskander RN
J Obstet Gynaecol; 2021 Aug; 41(6):956-961. PubMed ID: 33228421
[TBL] [Abstract][Full Text] [Related]
29. Complications and Survivorship Trends After Primary Debulking Surgery for Ovarian Cancer.
Xu Z; Becerra AZ; Justiniano CF; Aquina CT; Fleming FJ; Boscoe FP; Schymura MJ; Sinno AK; Chaoul J; Morrow GR; Minasian L; Temkin SM
J Surg Res; 2020 Feb; 246():34-41. PubMed ID: 31561176
[TBL] [Abstract][Full Text] [Related]
30. Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer.
Gillette-Cloven N; Burger RA; Monk BJ; McMeekin DS; Vasilev S; DiSaia PJ; Kohler MF
J Am Coll Surg; 2001 Dec; 193(6):626-32. PubMed ID: 11768679
[TBL] [Abstract][Full Text] [Related]
31. Perioperative fluid balance and major postoperative complications in surgery for advanced epithelial ovarian cancer.
Hasselgren E; Hertzberg D; Camderman T; Björne H; Salehi S
Gynecol Oncol; 2021 May; 161(2):402-407. PubMed ID: 33715894
[TBL] [Abstract][Full Text] [Related]
32. Surgical outcomes of diaphragmatic resection during cytoreductive surgery for advanced gynecological ovarian neoplasia: A randomized single center clinical trial - DRAGON.
Cianci S; Fedele C; Vizzielli G; Pasciuto T; Gueli Alletti S; Cosentino F; Chiantera V; Fagotti A; Scambia G
Gynecol Oncol; 2022 Feb; 164(2):271-277. PubMed ID: 34844774
[TBL] [Abstract][Full Text] [Related]
33. Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma.
Nasioudis D; Kahn R; Chapman-Davis E; Frey MK; Caputo TA; Witkin SS; Holcomb K
Gynecol Oncol; 2019 Aug; 154(2):401-404. PubMed ID: 31160074
[TBL] [Abstract][Full Text] [Related]
34. Clinical validation and comparison of the Comprehensive Complication Index and Clavien-Dindo classification in predicting post-operative outcomes after cytoreductive surgery in advanced ovarian cancer.
Kengsakul M; Nieuwenhuyzen-de Boer GM; Udomkarnjananun S; Kerr SJ; van Doorn HC; van Beekhuizen HJ
Int J Gynecol Cancer; 2023 Feb; 33(2):263-270. PubMed ID: 36600504
[TBL] [Abstract][Full Text] [Related]
35. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
[TBL] [Abstract][Full Text] [Related]
36. Laparoscopic management of advanced epithelial ovarian cancer after neoadjuvant chemotherapy: a phase II prospective multicenter non-randomized trial (the CILOVE study).
Pomel C; Akladios C; Lambaudie E; Rouzier R; Ferron G; Lecuru F; Classe JM; Fourchotte V; Paillocher N; Wattiez A; Montoriol PF; Thivat E; Beguinot M; Canis M
Int J Gynecol Cancer; 2021 Dec; 31(12):1572-1578. PubMed ID: 34670829
[TBL] [Abstract][Full Text] [Related]
37. The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer.
Angeles MA; Hernández A; Pérez-Benavente A; Cabarrou B; Spagnolo E; Rychlik A; Daboussi A; Migliorelli F; Bétrian S; Ferron G; Gil-Moreno A; Guyon F; Martinez A
Gynecol Oncol; 2022 Jul; 166(1):8-17. PubMed ID: 35568582
[TBL] [Abstract][Full Text] [Related]
38. Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events.
Straubhar AM; Wolf JL; Zhou MQC; Iasonos A; Cham S; Wright JD; Long Roche K; Chi DS; Zivanovic O
Gynecol Oncol; 2021 Feb; 160(2):438-444. PubMed ID: 33272645
[TBL] [Abstract][Full Text] [Related]
39. A radical approach to achieve complete cytoreductive surgery improve survival of patients with advanced ovarian cancer.
Liberale G; Pop CF; Polastro L; Kerger J; Moreau M; Chintinne M; Larsimont D; Nogaret JM; Veys I
J Visc Surg; 2020 Apr; 157(2):79-86. PubMed ID: 31837942
[TBL] [Abstract][Full Text] [Related]
40. The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.
Kim SR; Malcolmson J; Li X; Bernardini MQ; Hogen L; May T
Gynecol Oncol; 2021 Sep; 162(3):702-706. PubMed ID: 34256977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
